Researchers are interested in identifying "exceptional responders" to cancer medications to help highlight biomarkers that will identify patients likely to respond to treatment.
According to a study across all 32 cancer types, data suggest that 66% of mutations leading to cancer are the result of random events.
Gynecologic Cancers News
Clinicians are advocating that sexual dysfunction after cancer, which affects a large proportion of survivors, be addressed as a serious quality of life issue.
While survival rates of pediatric patients with cancer are greatly improved, researchers and clinicians are evaluating how to best preserve the reproductive potential of survivors.
More Gynecologic Cancers Information
This fact sheet educates patients about HPV vaccines, prevention, and cancer types associated with infection.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Overcoming Drug Resistance in the Treatment of Metastatic Breast Cancer
- Future Treatment Modalities in Sarcoma: Insights From ASCO 2017
- Dietary Nutrients and Oncogenic HPV Infections
- Vaccines Targeting Multiple Myeloma Offer Promising Therapeutic Approach
- In Focus: Abemaciclib for Advanced Breast Cancer
- Yoga Improves Sleep Disorders, Fatigue in Patients With Cancer
- Cryosurgery: The Future of Breast Cancer Treatment?
- Nivolumab With Ipilimumab May Negate Need for Whole Brain Radiotherapy in Melanoma With Brain Metastases
- Aldoxorubicin Improves Outcomes in Relapsed/Refractory Sarcoma
- Green Tea and Cancer
- First-line Nivolumab Fails To Prolong Survival in Stage IV NSCLC
- Pembrolizumab Shows Activity Among Some Young Patients With Advanced Sarcoma
- Potential Clinical Benefit in Multigene Hereditary Testing for Patients With Sarcoma
- Q&A With Filippo Montemurro, MD: Considerations for Treatment With Trastuzumab Emtansine
- Early Taxane Switching May Improve PSA Response Rates in Prostate Cancer